San Diego-based Cadence Pharmaceuticals, which licenses, develops, and commercializes biopharmaceuticals, said Tuesday that it has reached an agreement to raise approximately $86.6M from a group of venture capital investors. The publicly held firm said that the funding was led by Venrock, and also included Frazier Healthcare Ventures, Domain Associates, Versant Ventures, New Enterprise Associates, Bay City Capital and T. Rowe Price Associates. More information »